戻る
「早戻しボタン」を押すと検索画面に戻ります。

今後説明を表示しない

[OK]

コーパス検索結果 (1語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 e effects found for exogenously administered adenosine agonists.
2 eta, IL-6, and IL-8 mRNA were not changed by adenosine agonists.
3                                          The adenosine agonist 2-phenylaminoadenosine (PAD) stimulate
4                             The nonselective adenosine agonist 5'-N-ethylcarboxamidoadenosine (NECA)
5 ulated with IL-1 and either the nonselective adenosine agonist 5'-N-ethylcarboxamidoadenosine (NECA)
6 treatments in the presence and absence of an adenosine agonist and antagonist.
7 f this study was to determine the effects of adenosine agonists and an antagonist on ischemia-induced
8 imulation frequencies and in the presence of adenosine agonists and antagonists.
9 f ICB CHA suggesting cross-tolerance between adenosine agonists and cannabinoids.
10 lls and primary neurons after treatment with adenosine agonists and PACAP.
11             Previous studies have shown that adenosine agonists are effective in reducing intraocular
12 osine receptor agonist NECA but not the A(1)-adenosine agonist CCPA replicated the adenosine effect.
13   These effects were reproduced by using the adenosine agonist CGS 21680 and were counteracted with t
14              These data demonstrate that the adenosine agonist CHA lowers IOP in a dose-related fashi
15           These studies demonstrate that the adenosine agonist CHA significantly increases convention
16 hod for determining specificity of synthetic adenosine agonist compounds for the A2A and A2B receptor
17 and allowing us to isolate the most specific adenosine agonist compounds.
18                                              Adenosine agonist concentrations that abrogated cytokine
19  liquid culture gave ED50 values for various adenosine agonists consistent with reported Kd alpha val
20        Contrary to expectations, neither the adenosine agonists (CPA, propentofylline) nor the antago
21  Adenosine and dipyridamole are nonselective adenosine agonists currently used as pharmacologic stres
22  with the ocular hypotensive response to the adenosine agonist cyclohexyladenosine (CHA).
23                                              Adenosine agonist-dependent growth response of yeast str
24 alent linking of functionalized congeners of adenosine agonists, each being selective for either the
25     While simple carbocyclic substitution of adenosine agonists greatly diminishes potency, methanoca
26                                      Because adenosine agonists have antiinflammatory effects, and be
27 affinity of ribose-containing ligands (i.e., adenosine agonists) have been identified in both TM3 and
28 ng apical as well as basolateral delivery of adenosine agonists in varying renal preparations.
29 of Gly-14 in TM1 to Thr-14, the affinity for adenosine agonists increased 100-fold, and after Pro-25
30 ylate (BTH4, 7; Figure 1), which antagonized adenosine agonist-induced inhibition of adenylyl cyclase
31 receptors and mechanisms responsible for the adenosine agonist-induced rise in IOP.
32  with a KB value of 1.62 +/- 0.73 microM and adenosine agonist-induced stimulation of adenylyl cyclas
33                                              Adenosine agonists inhibit TNF-alpha production in macro
34             Previous studies have shown that adenosine agonists may induce a rise in intraocular pres
35 timulated CGRP release and suggest that A(1) adenosine agonists may warrant further investigation in
36 erebellar administration of the A1-selective adenosine agonist, N6-cyclohexyladenosine (CHA) on ethan
37                                          The adenosine agonist NECA (100 micromol/L) increased interl
38  receptor transcripts, only the nonselective adenosine agonist NECA (5'-N-ethylcarboxamidoadenosine),
39       The ocular effects of the nonselective adenosine agonist NECA, the relatively selective adenosi
40   Activation of the current by serotonin and adenosine agonists occurred with a time constant of 200-
41                                              Adenosine agonists or adenosine regulating agents have p
42               The stimulatory actions of the adenosine agonist PIA on IR-beta-EP release and on cAMP
43                                              Adenosine agonists reduced IPSCs with the following rank
44 (-7) M), but only in the presence of PIA, an adenosine agonist that inhibits the cyclic AMP pathway.
45             After a 20-min treatment with an adenosine agonist, the desensitization of A2a and A2b re
46          High affinity binding sites for A2a adenosine agonists were detected in yeast membranes cont

WebLSDに未収録の専門用語(用法)は "新規対訳" から投稿できます。